PolySciTech (www.polyscitech.com)
provides a variety of PEG-PLA block copolymers as well as cationic polymers
such as cationic CPLA derivatives and PEI derivatives. Recently combinations of
PEG-PLA block copolymers and cationic derivatives have been utilized for
delivery of SiRNA inducing apoptosis in cancer cells. Read more: Liu, Yang,
Yan-Hua Zhu, Cheng-Qiong Mao, Shuang Dou, Song Shen, Zi-Bin Tan, and Jun Wang.
"Triple Negative Breast Cancer Therapy with CDK1 siRNA Delivered by
Cationic Lipid Assisted PEG-PLA Nanoparticles." Journal of Controlled
Release (2014). http://www.sciencedirect.com/science/article/pii/S0168365914004702
“Abstract: There is no effective clinical therapy yet for
triple-negative breast cancer (TNBC) without particular human epidermal growth
factor receptor-2, estrogen and progesterone receptor expression. In this
study, we report a molecularly targeted and synthetic lethality-based siRNA
therapy for TNBC treatment, using cationic lipid assisted poly(ethylene
glycol)-b-poly(d,l-lactide) (PEG-PLA) nanoparticles as the siRNA carrier. It is
demonstrated that only in c-Myc overexpressed TNBC cells, while not in normal
mammary epithelial cells, delivery of siRNA targeting cyclin-dependent kinase 1
(CDK1) with the nanoparticle carrier (NPsiCDK1) induces cell viability decreasing
and cell apoptosis through RNAi-mediated CDK1 expression inhibition, indicating
the synthetic lethality between c-Myc with CDK1 in TNBC cells. Moreover,
systemic delivery of NPsiCDK1 is able to suppress tumor growth in mice bearing
SUM149 and BT549 xenograft and cause no systemic toxicity or activate the
innate immune response, suggesting the therapeutic promise with such
nanoparticles carrying siCDK1 for c-Myc overexpressed triple negative breast
cancer. Keywords: Triple-negative breast cancer; Synthetic lethality; siRNA
delivery; Cationic lipid assisted nanoparticle; Cyclin-dependent kinase 1”
No comments:
Post a Comment